Sponsors should be aware of the significant implications the Addendum is likely to have on clinical trial planning, conduct, statistical analysis, and interpretation.
Ülker Aydemir
Advertisement
Articles by Ülker Aydemir
Advertisement
Latest Updated Articles
- Estimands and Implications for Sponsors as ICH E9 (R1) Addendum Progresses
Published: December 13th 2017 | Updated:
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
Life Sciences Can’t Afford Fragmented Data and Disconnected Teams
2
FDA Approves Subcutaneous Lunsumio VELO Based on GO29781 Trial Results in Relapsed or Refractory Follicular Lymphoma
3
Applying AI to Automate Workflows Without Disrupting Sites
4
ACT Brief: Building a Digital Thread in Life Sciences, CRO Sourcing Decisions and Site Burden, and Lilly’s Oral GLP-1 Phase III Results
5